CABA
NASDAQ
US
Cabaletta Bio, Inc. - Common Stock
$2,96
▲ +$0,28
(+10,45%)
Vol. 2.1M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$210.8M
ROE
-107,1%
D/E
15,88
Beta
3,27
52W
$1–$4
Consenso Wall Street
16 analisti · Apr 20266
Acquisto forte
7
Compra
3
Mantieni
0
Vendi
0
Vendita forte
81,2%
Rating Compra
Grafico dei Prezzi
Titoli simili
IVVD
Invivyd Inc
$684.5M
IMRX
Immuneering Corp
$424.9M
PBYI
Puma Biotechnology Inc
P/E 8,1
$299.8M
DMAC
DiaMedica Therapeutics Inc
$414.5M
XOMA
Xoma Royalty Corp
P/E 15,2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
Utili
Tasso di battuta: 40,0%
Prossimo report
Mag 13, 2026
Stima EPS: $-0,41
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,41 | — | — |
| Dic 2025 | $-0,47 | $-0,40 | +$0,07 |
| Set 2025 | $-0,48 | $-0,44 | +$0,04 |
| Giu 2025 | $-0,66 | $-0,73 | $-0,07 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$30.6M | -$32.6M | -$35.9M | -$45.1M | -$44.9M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -92.1% | -92.1% | -92.1% | -92.1% | -107.1% | -107.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 11.39 | 11.39 | 11.39 | 11.39 | 15.88 | 15.88 |
| Current Ratio | 4.78 | 4.78 | 4.78 | 4.78 | 3.60 | 3.60 |
Rapporti chiave
ROA (TTM)
-83,0%
P/B
0,7
EPS (TTM)
$-2,51
CF/Share
$-1,64
52W High
$3,67
52W Low
$0,99
$0,99
Intervallo 52 settimane
$3,67
Salute finanziaria
Flusso di cassa libero
-$34.6M
Debito netto
-$34.4M
Liquidità
$60.2M
Debito totale
$25.8M
Aggiornato al Set 30, 2025
Як CABA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CABA vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
0,7
▼
70%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CABA vs аналоги Biotechnology
ROE
-107,1%
▼
59%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-83,0%
▼
78%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя CABA vs аналоги Biotechnology
D/E ratio
15,9
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
3,6
▼
19%
sotto
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
3,3
▲
237%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CABA
CABA
Mediana peer
Industria
CABA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CABA vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
SIMON MARK
Director · Gen 21
11061 shs
NICHTBERGER STEVEN
Chief Executive Officer · Gen 21
45000 shs
TOMASELLO SHAWN CLINE
Director · Gen 21
22725 shs
CHANG DAVID J. M.D.
Officer · Gen 21
8800 shs
BOLLARD CATHERINE M.D.
Director · Gen 21
4405 shs
BINDER GWENDOLYN
Officer · Gen 21
11312 shs
GERARD MICHAEL
General Counsel · Gen 21
6600 shs
GAVEL STEVE
Officer · Gen 21
22170 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 43,3%T. Rowe Price Investment Ma…
10,24%
$26.4M
Bain Capital Life Sciences …
10,05%
$25.9M
Jennison Associates LLC
9,25%
$23.9M
Adage Capital Partners GP L…
9,17%
$23.7M
Vanguard Group Inc
4,59%
$11.8M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora